Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact Authors: Dídac Mauricio, Virginia Pascual, Maria Soler, Francisco J Pérez-Sádaba Published: 2026 ABSTRACT AbstractIntroductionType 2 diabetes mellitus (T2DM) imposes a clinical and economic burden, largely due to its long-term micro- and macrovascular complications. To prevent these complications, treatment adherence is essential. The aim of this study was to analyse basal insulin adherence and its clinical and economic repercussions in patients with T2DM in Spain.MethodsRetrospective, descriptive observational study using the Spanish Health Improvement Network (THIN®) database. Adult patients with T2DM, a registry entry of first basal insulin prescription from January 2014, and prescription/dispensation records between January 2014 and January 2024 were included. Adherence was estimated as proportion of days covered ≥ 80% in patients with ≥ 1 (full-population) and ≥ 3 years of follow-up (≥ 3 years subpopulation). Sociodemographic, clinical characteristics, micro- and macrovascular complications incidence, healthcare resource use (HCRU) (outpatient general practitioner/nursing/specialists visits and laboratory tests), and sick leave were analysed in adherent and non-adherent patients of the ≥ 3 years subpopulation. Direct (complications + HCRU) and indirect costs were calculated.ResultsA total of 9441 patients in the full-population and 4693 in the ≥ 3 years subpopulation were included. Less than 70% were adherent (66.90% and 69.51%, respectively). Although adherent patients tended to be older and more were retired, sociodemographic and clinical characteristics were consistent in adherent and non-adherent patients. In both groups, 17–20% had micro- and 30–40% had macrovascular complications, but non-adherent patients showed increases of 5.54% and 15.90% in annual complications. Mean annual costs for micro- and/or macrovascular complications were €1091.68 for adherent and €1306.45 for non-adherent patients. Mean annual direct and indirect costs were €1528.45 and €784.97 in adherent and €1651.39 and €952.89 in non-adherent patients.ConclusionThis study shows less than 70% adherence to basal insulin under routine clinical practice in Spain and reveals unmet needs in current T2DM therapies. Non-adherence could result in more complications, which would lead to higher costs for the healthcare system.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13300-026-01892-2.Keywords: Type 2 diabetes mellitus, Basal insulin, Adherence, HCRU, Micro- and macrovascular complications Key Summary Points Why carry out this study? Type 2 diabetes mellitus (T2DM) imposes a clinical and economic burden, largely due to its long-term micro- and macrovascular complications. To prevent these complications, treatment adherence is essential. The aim of this study was to analyse basal insulin adherence and its clinical and economic repercussions in patients with T2DM in Spain.What was learned from the study? Less than 70% of patients with T2DM were adherent to basal insulin under routine clinical practice conditions in Spain. Non-adherent patients had a higher number of annual macrovascular complications and higher direct costs. There are unmet needs in current T2DM therapies that may increase adherence of patients with T2DM to basal insulin in Spain. Improving adherence to basal insulin in patients with T2DM may help mitigate the burden of macrovascular complications and optimize healthcare resource utilization within the Spanish National Health System. Introduction Diabetes mellitus (DM) has emerged as a major global public health issue. According to the International Diabetes Federation, 537 million adults worldwide have DM [1]. Type 2 diabetes mellitus (T2DM) is the most common type of DM, representing 90% of all cases [1, 2]. T2DM is a chronic, highly heterogeneous, multifactorial and progressive disease, characterized by inherited or acquired insulin resistance and insulin secretion alterations [3]. In Spain, T2DM affects 13.80% of the adult population [4], with an incidence of 11.60 new cases per 1000 person-years [5]. T2DM imposes a significant economic and clinical burden. DM annual costs in Spain are estimated to exceed 5.8 million euros [6]. Specifically for patients with T2DM, an average annual cost of €1305 to €4278 per person is spent as direct costs [7–9]. In 2021, T2DM represented 6.34% of the total years lived with disability and 3.88% of the total disability-adjusted life years in Spain [10]. Long-term complications of T2DM, such as micro- and macrovascular, may be an important driver of its economic and clinical burden [7, 11]. On the one hand, adults with DM have two to four times increased risk of cardiovascular disease such as myocardial infarction, coronary heart disease, peripheral artery disease, heart failure and stroke than adults without DM [12]. In fact, cardiovascular disease is the main cause of morbidity and mortality in patients with T2DM [12]. On the other hand, T2DM microvascular complications such as nephropathy, retinopathy and neuropathy are responsible for a considerable increase in morbidity and a substantial impairment in the quality of life in people with T2DM [12]. The CODE-2 study reported that suffering from either T2DM microvascular, macrovascular or both implied 1.59, 2.29 and 2.42 times higher costs than not suffering from them [7]. Current treatments for T2DM aim to prevent or delay the appearance of chronic complications, improving patients’ life expectancy and quality of life [13]. Treatment adherence is essential for the success of T2DM management and glycaemic control. High levels of adherence to antidiabetic medications are associated with improved glycaemic control, reduced risk of complications, and lower healthcare costs [14–16]. Less is known about adherence to basal insulin specifically, but some studies suggest that a significant proportion of patients with T2DM receiving insulin usually show lower adherence [17, 18]. As evidence on the adherence to basal insulin is scarce, the aim of this study was to analyse patient adherence to basal insulin and the associated clinical and economic repercussions in patients with T2DM in Spain. The secondary objectives were to describe the micro- and macrovascular T2DM-related complications, and the healthcare resource use (HCRU) based on basal insulin adherence. Methods Study Design and Setting This was a retrospective, descriptive observational study using the Spanish Health Improvement Network (THIN®) database (Cegedim Health Data, Spain). The THIN® database is a longitudinal, patient-level, anonymized database providing access to electronic health records from primary care, specialist care, and pharmacy dispensing across different autonomous communities in Spain. It includes data from more than 1.9 million patients, from 1900 general practitioners and 2500 specialists of 300 Spanish centres since 2014 [19]. The THIN® database exhibits good external validity for real-world evidence research in Spain, as demonstrated by its alignment with age and gender demographics, disease prevalence, and prescribed medications [20]. For this study, registries of patients with T2DM from January 2014 to January 2024 (data extraction date) were analysed. Data from specialist care in the THIN® database are limited to records of outpatient visits in which a treatment prescription is registered. Population Eligible subjects were adult patients with T2DM with a registry entry of basal insulin prescription in the THIN® database during the study period starting in January 2014, with available prescription and dispensing records during the follow-up period between January 2014 and January 2024. As prior insulin use before this period could not be determined, analyses were based on the earliest basal insulin prescription recorded within the observation period. Patients were identified based on recorded basal insulin prescriptions; information on treatment initiation criteria or alternative therapies was not available in the database. Study Variables and Outcomes The prescription and dispensation registries of all prescribed basal insulins (ATC A10AE) per patient were extracted for the whole available follow-up to analyse patient adherence. Patient adherence to basal insulin was defined as the proportion of days covered (PDC). Patients were classified as adherent if PDC was ≥ 80% (the maximum could be higher than 100% since it was considered that there could be a remnant). The PDC was calculated as the number of days covered by a basal insulin dispensation divided by the number of theoretical days based on prescription data. Adherence was assessed only during periods with an active basal insulin prescription; periods without a recorded prescription (e.g. basal insulin discontinuation) were not considered in the PDC calculation. The adherence rate was evaluated in the total T2DM population in the THIN® database that fulfilled the eligibility criteria and had at least 1 year of follow-up since the first prescription of basal insulin (“full population”), but also in the patients with at least 3 years (“≥ 3 years” subpopulation) of follow-up available. The remaining outcomes were assessed for patients of the “≥ 3 years” subpopulation, as it was expected that micro- and macrovascular events would occur in the long term in these patients. Sociodemographic and clinical characteristics measured at the time of the earliest basal insulin prescription recorded in the THIN® database of each patient during the study period (between 2014 and 2018) (index date) included age, sex, working status and comorbidities. The analysed comorbidities included diabetes-related microvascular complications, cardiovascular disease, cerebrovascular disease, peripheral arterial disease, hypercholesterolemia and hypertension (presence of ICD-9-CM: 250.5 [362.01–362.07]; 250.6 [357.2]; 250.4 [583.81]; 410–414; 443.9; 429.2, 401.0–401.9, any time prior or at index date). During follow-up, database entries of the microvascular complications retinopathy, polyneuropathy and/or nephropathy (presence of ICD-9-CM: 250.5 [362.01–362.07]; 250.6 [357.2]; 250.4 [583.81]) and the macrovascular complications ischemic heart disease, acute myocardial infarction, peripheral vascular disease and/or cerebrovascular disease (with and without infarction), angina pectoris, atherosclerosis (presence of ICD-9-CM: 410–414; 443.9; 429.2) were analysed, as recorded in electronic health records when subsequently documented, regardless of the initial care setting. HCRU from index date to the end of available follow-up were measured based on laboratory tests for any clinical reason (blood, urine and endocrine tests) and general practitioner (GP), specialist and nursing visits with a registry entry associated with T2DM (ICD-9-CM: 250.00) and with the micro- and/or macrovascular complications. Only records of outpatient visits in which treatment was prescribed were registered in the THIN® database and considered for the analysis. The pharmacological cost was not included in any case. The number of patients with a registry entry of TD2M-related and micro- and macrovascular complications-related sick leave and their length were recorded. Sick leave corresponded to primary care records in which the main diagnosis was T2DM or one of the micro- or macrovascular complications included in the study, identified using the same ICD-9-CM codes applied elsewhere in the analysis. The cumulative number and duration of sick leave days were calculated over the entire follow-up period per patient. Sick leave was considered only for patients with employed working status at the time the sick leave was registered. Statistical Analyses The number of the T2DM-related micro- and macrovascular complications per patient and per year was calculated in the adherent and non-adherent patients. Macrovascular complications were considered if they required hospitalisation, and their cost was extracted from Minimum Basic Data Set (MBDS) [21]. These costs correspond to standardised hospitalisation-related tariffs assigned to each diagnosis, reflecting the overall inpatient resource use captured in the Spanish public healthcare system. Moreover, in order to estimate the cost of microvascular complications, their unit costs for management were considered [22]. These unit costs represent aggregate tariffs associated with each complication, based on official data from Spanish autonomous communities and the literature. Average tariffs across autonomous communities were used to ensure national representativeness. HCRU was estimated by determining the utilisation of resources used at the individual patient level during the available follow-up and were calculated in the adherent and non-adherent patients. Total direct costs were estimated as annual cost per patient associated with the GP, specialist and nursing visits, laboratory tests and with the management costs of the micro- and macrovascular complications. For this study, no treatment costs were considered. The cost for each resource was estimated as the product between the frequency of use and unit cost, using average unit costs derived from standard tariffs published by Spanish autonomous communities and compiled in the eSalud database [22]. Total indirect costs were estimated as the annual cost per patient associated with the sick leave of the active population at the time of the registered sick leave, considering the Spanish average salary [23]. Costs were considered in 2024 euros. The unit costs used are shown in Supplementary Table S1. Absolute and relative frequencies were calculated to describe qualitative variables, whereas centrality and dispersion measures (mean, standard deviation, quartiles, minimum and maximum) were calculated for quantitative variables. STATA v.14 was used for data analysis. Statistical analyses are performed on valid data, i.e. on the number of patients with the corresponding variable recorded in each case. Compliance with Ethics Guidelines The study was conducted in accordance with the Declaration of Helsinki and it was evaluated and approved by the Clinical Research Ethics Committee at Hospital Clínic de Barcelona (approval reference number HCB/2023/1115). Because of the retrospective design of the study and that THIN® is an anonymized database where patients cannot be identified, the Clinical Research Ethics Committee approved the waiver of informed consent. This study used anonymised, project-specific data extracts from the THIN® database, with permission from the database owner. The authors did not have access to the underlying source database. Results Patients’ Adherence to Basal Insulin Treatment A total of 9441 and 4693 patients with T2DM treated with basal insulin had at least 1 year (“full population”) or 3 years (“≥ 3 years” subpopulation) of follow-up available in the THIN® database (of outpatient visits in which treatment was prescribed), between January 2014 and January 2024 (data extraction date), respectively. According to the criterion of PDC ≥ 80% for adherence, 66.90% and 69.51% were adherent, respectively. Sociodemographic and Clinical Characteristics The sociodemographic and clinical characteristics of the ≥ 3 years subpopulation at the time of the earliest basal insulin prescription recorded in the THIN® database during the study period are shown in Table 1. At that time, the mean (SD) age was 62.42 (12.78) and 56.42 (15.57) years in the adherent and non-adherent patients, respectively. At index date, 66.36% of the adherent patients and 45.31% of the non-adherent patients were retired. The rest of the baseline characteristics were consistent in the total ≥ 3 years subpopulation and in both groups. Table 1Sociodemographic and clinical characteristics at index date of the ≥ 3 years subpopulationCharacteristicsTotal (N = 4693)Adherent (N = 3262)Non-adherent (N = 1431)Age (years), mean (SD)60.59 (13.97)62.42 (12.78)56.42 (15.57)Female, n (%)2141 (45.62%)1492 (45.74%)649 (45.35%)Comorbidities, n (%) Diabetes-related microvascular complications4514 (96.19%)3133 (96.05%)1381 (96.51%) Cardiovascular disease2237 (47.67%)1565 (47.98%)672 (46.96%) Cerebrovascular disease277 (5.90%)188 (5.76%)89 (6.22%) Peripheral arterial disease6 (0.13%)4 (0.12%)2 (0.14%) Hypercholesterolemia2698 (57.49%)1895 (58.09%)803 (56.11%) Hypertension2914 (62.09%)2012 (61.68%)902 (63.03%)Working status, n (%)N = 4607N = 3199N = 1408 Employed1347 (29.24%)779 (24.35%)568 (40.34%) Unemployed240 (5.21%)146 (4.56%)94 (6.68%) Benefits/social insertion47 (1.02%)30 (0.94%)17 (1.21%) Retired2761 (59.93%)2123 (66.36%)638 (45.31%) Othera212 (4.60%)121 (3.78%)91 (6.46%)aIncludes patients with working situations not captured by the other categories, including special situations Sociodemographic and clinical characteristics at index date of the ≥ 3 years subpopulation aIncludes patients with working situations not captured by the other categories, including special situations T2DM-Related Micro- and Macrovascular Complications Incidence and Costs Based on Basal Insulin Adherence In the ≥ 3 years subpopulation, 19.83% adherent and 17.33% non-adherent patients suffered at least one microvascular complication during follow-up. Adherent patients had a mean (SD) of 0.16 (0.08) microvascular complications per year, while the non-adherent patients had a mean of 0.17 (0.10) (Fig. 1a). Type 2 diabetes mellitus-related micro- and macrovascular complications during follow-up of adherent and non-adherent patients in the ≥ 3 years subpopulation Regarding macrovascular complications, 38.04% adherent and 31.38% non-adherent patients suffered at least one macrovascular complication during follow-up. Adherent patients had a mean of 0.21 (0.11) complications per year. Non-adherent patients had a mean of 0.25 (0.18) (Fig. 1a). In the ≥ 3 years subpopulation, the total mean (SD) annual costs for managing the complications in patients suffering from either any micro- and/or macrovascular complications were €1091.68 (840.70) for adherent patients and €1306.45 (1185.68) for non-adherent patients (Fig. 1b). The management of macrovascular complications had a higher impact on total direct costs that microvascular complications (€1342.46 vs €65.68 in adherent patients; €1574.86 vs €72.44 in non-adherent patients). T2DM-Related HCRU and Associated Costs Based on Basal Insulin Adherence In both groups, the GP visits were the HCRU that implied the highest annual cost, followed by laboratory tests (Table 2). Table 2HCRU and associated costs per year of adherent and non-adherent patients in ≥ 3 years subpopulationAdherentNon-adherentGeneral practitioner visits per yearN = 3261N = 1430 Visits, mean (SD)7.45 (3.69)6.46 (3.58) Costs (€), mean (SD)€446.21 (220.84)€387.19 (214.71)Specialist visit per yearaN = 3059N = 1376 Visits, mean (SD)1.85 (1.94)1.93 (1.85) Costs (€), mean (SD)€208.03 (218.48)€216.82 (207.81)Nursing visits per yearaN = 3242N = 1425 Visits, mean (SD)4.18 (3.81)4.04 (4.52) Costs (€), mean (SD)€102.00 (93.12)€98.67 (110.28)Laboratory testsb per yearN = 3231N = 1401 Tests, mean (SD)32.34 (24.73)27.78 (22.33) Costs (€), mean (SD)€388.80 (296.42)€335.11 (268.39)HCRU healthcare resource use, SD standard deviationaOnly HCRU records associated with outpatient visits in which treatment was prescribed were consideredbBlood, urine and endocrine tests HCRU and associated costs per year of adherent and non-adherent patients in ≥ 3 years subpopulation HCRU healthcare resource use, SD standard deviation aOnly HCRU records associated with outpatient visits in which treatment was prescribed were considered bBlood, urine and endocrine tests If both HCRU (laboratory tests, GP, specialist and nursing visits) and T2DM-related micro- and macrovascular complications management costs are considered, the mean (SD) total annual direct costs of non-adherent patients in the total ≥ 3 years subpopulation were €1651.39 (1129.62), which represented an increase of 7.44% over the costs in adherent patients (€1528.45 [1299.46]). T2DM-Related Societal Costs Based on Basal Insulin Adherence A total of 81 adherent patients and 71 non-adherent patients of the ≥ 3 years subpopulation who were employed at the time of assessment had at least one T2DM-related sick leave registry entry during the follow-up. The patients with registered T2DM-related sick leave had a mean (SD) length of the sick leave per year of 4.00 (4.06) days for adherent patients and of 4.45 (5.22) days for non-adherent patients (Table 3). Table 3Sick leave incidence, mean length and annual costs of adherent and non-adherent patients in the ≥ 3 years subpopulationEmployeda adherent (N = 3262)Employeda non-adherent (N = 1431)T2DM-related sick leave Incidence, N (%)81 (2.48%)71 (4.96%) Length per year (days),b mean (SD)4.00 (4.06)4.45 (5.22) Annual costs (€),a,b mean (SD)€470.09 (476.89)€522.22 (613.21)Complications-related sick leavec Incidence, N (%)60 (1.84%)38 (2.66%) Length per year (days),b mean (SD)8.92 (9.28)9.56 (8.32) Annual costs (€),a,b mean (SD)€1047.96 (1089.90)€1122.77 (977.41)aPatients who were employed at some point during follow-up were taken into accountbBased on patients with related sick leavecT2DM-related micro- and macrovascular complications Sick leave incidence, mean length and annual costs of adherent and non-adherent patients in the ≥ 3 years subpopulation aPatients who were employed at some point during follow-up were taken into account bBased on patients with related sick leave cT2DM-related micro- and macrovascular complications A total of 60 adherent patients and 38 non-adherent patients of the ≥ 3 years subpopulation had at least one micro- and/or macrovascular-related sick leave registry entry during follow-up. The mean (SD) length of the sick leave per year was 8.92 (9.28) days for adherent patients and 9.56 (8.32) days for non-adherent patients (Table 3). According to these results on sick leave, the associated total mean (SD) annual indirect costs of the employed adherent and non-adherent patients were €784.97 (918.75) and €952.89 (795.17), respectively. Discussion T2DM is a severe metabolic chronic disease that can lead to macrovascular and microvascular complications if adherence and therefore adequate glycaemic control are not achieved [13–15]. With this study, we aimed to analyse adherence to basal insulin of patients with T2DM in routine clinical practice in Spain, and the associated clinical and economic repercussions of non-adherence. As a result of its complex administration schedule and that patients are frequently on multiple medications (polypharmacy), insulin is a T2DM treatment with reported lower adherence rates than other T2DM treatments [17]. This study, based on the Spanish THIN® database, has shown a 66.90% adherence of patients with T2DM to basal insulin with at least 1 year of follow-up. Previous studies carried out in Europe show similar and lower adherence rates than in this study, ranging from 41% to 86% [24]. In line with Aroda et al., who identified older age as a predictor of adherence [25], in this study adherent patients tended to be older and a higher proportion of them were retired at the time of the first basal insulin prescription. Although increasing age is generally associated with a higher prevalence of complications and healthcare costs in type 2 diabetes [26, 27], in our descriptive analysis, older adherent patients did not show a higher burden of complications or costs, suggesting that age alone does not account for the observed patterns. Both groups showed equivalent comorbidity burden, but those who are younger may perceive themselves to be healthier and are less adherent. Any strategy, as reducing the treatment regimen, may enhance adherence in these younger and employed patients with a different lifestyle than older and retired people. In this study, approximately 17–20% and 30–40% of patients, with at least 3 years of follow-up, had micro- or macrovascular complications, respectively. The higher prevalence of macrovascular complications may be related to the more advanced disease stage of patients initiating basal insulin, in whom macrovascular complications are more frequently observed than microvascular complications in real-world settings [28]. Other studies have shown that adherent patients receiving insulin and oral antidiabetics had a lower probability of suffering from micro- and macrovascular diabetes complications [29, 30]. In non-adherent patients with micro- or macrovascular complications, an increase of 5.54% and 15.90% in the number of micro- and macrovascular complications per year was detected with respect to adherent patients, respectively. Therefore, these results suggest the beneficial effect of adherence reducing the number of complications in patients with T2DM prone to suffer complications. T2DM management imposes an economic burden. In Spain, around 8.2% of the health expenditure is spent in DM management [6]. The results of the present study suggest that good adherence may contribute to reducing this economic burden. In this study, managing T2DM-related complications in the non-adherent group caused 1.19 times higher costs of managing the complications in adherent patients in the ≥ 3 years subpopulation (€1306.45 and €1091.68, respectively). The CODE-2 study already reported that suffering from T2DM-related complications implied 2.42 times higher costs [7]. Taken together, these results suggest that suffering from complications increases costs, and non-adherence may increase them even more. Therefore, improving patient adherence could not only have repercussions on the incidence of the macrovascular complications but may also reduce the associated direct costs. In this study, GP visits and laboratory tests were the main drivers of HCRU costs with a tendency towards a higher number of GP visits and tests by adherent patients. Nevertheless, there seems to be a trend towards a greater number of specialist visits in non-adherent patients. Other studies evaluating HCRU costs in adherent and non-adherent patients have already shown higher outpatient HCRU costs in non-adherent patients [25]. If management of the micro- and macrovascular complications and HCRU costs (laboratory tests, GP, specialist and nursing outpatient visits) are considered, the total mean annual direct costs were €1528.45 in adherent patients and €1651.39 in non-adherent patients. The increase in total direct costs observed in non-adherent patients of this study may be therefore mainly attributed to T2DM macrovascular complications management. Regarding total direct costs, Perez-Nieves et al. reported both lower diabetes-related and all-cause costs for adherent patients in the USA [31]. Aroda and colleagues and Eby et al. also described lower all-cause medical costs for adherent patients in the USA [16, 25]. It was previously reported that the productivity losses attributable to T2DM work absenteeism and permanent disability also account for a cost of €1774 per patient per year [32]. In this study, patients’ mean annual indirect costs of the ≥ 3 years subpopulation due to work absenteeism ranged from €784.97 in adherent patients to €952.89 in non-adherent patients. Differences may be attributed to the fact that the present study did not consider the costs associated with permanent disability, which Ballesta et al. did take into account [32]. These results suggest that adherence was linked to a trend towards reduced productivity losses and indirect costs. Limitations of our analysis include the use of retrospective data limited to that registered in the THIN® database from 2014 to 2024 which includes records of primary care, specialist care, and pharmacy dispensing. For specialist care, only outpatient visits in which a treatment prescription was recorded were available. Acute care data were not directly captured, unless subsequently recorded in primary care records. In addition, adherence to basal insulin was estimated with PDC, which is based on the available prescription and dispensing records in the THIN® database but not on actual patient usage. While PDC may overestimate actual adherence and reflects overall adherence during the observation period without allowing identification of short-term fluctuations or the precise timing of periods of adherence and non-adherence, it is usually accepted and widely used as a good and more conservative estimate for adherence than other measures such as the medication possession ratio [33]. Analyses were based on the earliest basal insulin prescription recorded within the study period; information on prior insulin use before this period was not available. In addition, the reasons for non-adherence could not be assessed, including potential clinical factors such as hypoglycaemia. Furthermore, no treatment costs were considered in this study. Higher treatment costs have been reported in adherent patients [31]. This would dilute the aim of this study of assessing the clinical and economic impact of non-adherence. With this purpose, the study focused on the impact of non-adherence on the micro- and macrovascular complications and HCRU, as these were previously reported to be influenced by adherence [14–16]. Moreover, a conservative approach was adopted as treatment costs associated with the micro- and macrovascular complications, expected to be higher in non-adherent patients, were also not considered. In addition, the analyses were performed on the basis of valid data. It was assumed that patients with no registry entry in the THIN® database had not suffered the complication, used the HCRU or had a sick leave. Sex- and gender-specific analyses were not performed, as they were outside the predefined scope of this descriptive study and are not expected to materially affect the interpretation of the findings. Conclusions This study has shown less than 70% adherence to basal insulin under routine clinical practice conditions in Spain and highlights that there are needs not covered by current T2DM therapies. The data from this study suggest that young patients are less adherent, and non-adherence results in more complications that could lead to higher costs to the healthcare system. Therefore, this study reinforces that the achievement of good adherence is essential and must be a goal for present and future T2DM treatments. Any T2DM treatment characteristics of future treatments, such as patient convenience, that may correlate with better adherence outcomes will be extremely valuable for the health system and, more importantly, for patients with T2DM who will benefit from improved life expectancy and quality of life and clinical outcomes. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 127 KB) Acknowledgments Medical Writing/Editorial Assistance Medical writing support was provided by Ester de la Cruz, employee of Outcomes′10 (a ProductLife Group Company), who received honoraria for medical writing funded by Novo Nordisk. Author Contribution Dídac Mauricio, Virginia Pascual, Maria Soler and Francisco J Pérez-Sádaba contributed to the conception and design of the study, to the analysis and interpretation of data and to the first draft and revision of the manuscript. All authors revised and approved the final version of the manuscript and accept responsibility for the accuracy and integrity of the final manuscript as submitted. Funding This study was financed by Novo Nordisk. The journal’s Rapid Service Fee was funded by Novo Nordisk. Data Availability The datasets generated during and/or analyzed during the current study are not publicly available due to restrictions related to data access agreements with the database owner and the use of anonymised, project-specific data extracts provided to the authors within the scope of this study; access to the full underlying database is restricted to the database owner. Declarations Conflict of Interest Dídac Mauricio has provided advisory services in the project. Virginia Pascual is an employee of Novo Nordisk. Maria Soler and Francisco J Pérez-Sádaba work for an independent research entity and have received fees for their contribution to project development and medical writing. Ethical Approval The study was conducted in accordance with the Declaration of Helsinki and it was evaluated and approved by the Clinical Research Ethics Committee at Hospital Clínic de Barcelona (approval reference number HCB/2023/1115). Because of the retrospective design of the study and that THIN® is an anonymized database where patients cannot be identified, the Clinical Research Ethics Committee approved the waiver of informed consent. This study used anonymised, project‑specific data extracts from the THIN® database, with permission from the database owner. The authors did not have access to the underlying source database. References Associated Data Supplementary Materials Supplementary file1 (PDF 127 KB) Data Availability Statement The datasets generated during and/or analyzed during the current study are not publicly available due to restrictions related to data access agreements with the database owner and the use of anonymised, project-specific data extracts provided to the authors within the scope of this study; access to the full underlying database is restricted to the database owner.